Proteomics International Laboratories Ltd (PIQ)

Overview

Proteomics International Laboratories Limited is a pioneering medical technology entity dedicated to proteomics, the study of proteins and their functions. The company, established in 2001 and headquartered in Perth, Australia, has positioned itself at the forefront of predictive diagnostics and analytical services. It capitalizes on advanced proteomics research and technology to develop diagnostic tests and offer specialized analytical services, catering to a global clientele with a keen focus on addressing critical medical conditions and enhancing patient care.

Products and Services

• PromarkerD:

A revolutionary predictive test specifically designed for diabetic kidney disease. Utilizing cutting-edge proteomics technology, PromarkerD aims to forecast the onset of this condition, enabling early intervention and better management to potentially slow or halt disease progression.

• Diagnostic Tests for Endometriosis and Giardia:

Continuing its commitment to advancing patient care, Proteomics International develops diagnostic tests that address endometriosis, a challenging and often painful disorder affecting women, and giardia, an intestinal infection caused by the Giardia lamblia parasite. These diagnostic tests are critical in the timely and accurate identification of these conditions, leading to more effective treatment strategies.

• Analytical Services:

Aside from its diagnostic products, Proteomics International Laboratories offers a range of analytical services. This includes specialist contract research designed to meet the various needs of the biotechnology, pharmaceutical, and healthcare industries. With a focus on proteomics, these services aid in the discovery and development of new drugs, therapeutic targets, and understanding disease mechanisms.